cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5517/ccdc.csd.cc2258l4
title: CCDC 1911695: Experimental Crystal Structure Determination

description: Related Article: Filip Zechel, Peter Schwendt, Róbert Gyepes, Ján Šimunek, Jozef Tatiersky, Lukáš Krivosudský|2019|New J.Chem.|43|17696|doi:10.1039/C9NJ02275A
DOI: 10.5517/ccdc.csd.cc2258n6
title: CCDC 1911697: Experimental Crystal Structure Determination

description: Related Article: Filip Zechel, Peter Schwendt, Róbert Gyepes, Ján Šimunek, Jozef Tatiersky, Lukáš Krivosudský|2019|New J.Chem.|43|17696|doi:10.1039/C9NJ02275A
DOI: 10.5517/ccdc.csd.cc225gj8
title: CCDC 1911879: Experimental Crystal Structure Determination

description: Related Article: Mathias Paul, Katrin Peckelsen, Thomas Thomulka, Jörg Neudörfl, Jonathan Martens, Giel Berden, Jos Oomens, Albrecht Berkessel, Anthony J. H. M. Meijer, Mathias Schäfer|2019|Phys.Chem.Chem.Phys.(PCCP)|21|16591|doi:10.1039/C9CP02316J
DOI: 10.5517/ccdc.csd.cc22bvz8
title: CCDC 1917070: Experimental Crystal Structure Determination

description: Related Article: Stephanie A. Boer, Pei-Xi Wang, Mark J. MacLachlan, Nicholas G. White|2019|Cryst.Growth Des.|19|4829|doi:10.1021/acs.cgd.9b00801
DOI: 10.5517/ccdc.csd.cc22cx5k
title: CCDC 1918068: Experimental Crystal Structure Determination

description: Related Article: Kazuto Takaishi,  Sakiko Hinoide,  Tomoki Matsumoto,  Tadashi Ema|2019|J.Am.Chem.Soc.|141|11852|doi:10.1021/jacs.9b06240
DOI: 10.5517/ccdc.csd.cc22dq8h
title: CCDC 1918846: Experimental Crystal Structure Determination

description: Related Article: Moritz Balkenhohl, Dorothée S. Ziegler, Alexandre Desaintjean, Leonie J. Bole, Alan R. Kennedy, Eva Hevia, Paul Knochel|2019|Angew.Chem.,Int.Ed.|58|12898|doi:10.1002/anie.201906898
DOI: 10.5517/ccdc.csd.cc22hfjk
title: CCDC 1921458: Experimental Crystal Structure Determination

description: Related Article: Quentin Foucart, Yuna Shimadate, Jérôme Marrot, Atsushi Kato, Jérôme Désiré, Yves Blériot|2019|Org.Biomol.Chem.|17|7204|doi:10.1039/C9OB01402K
DOI: 10.5517/ccdc.csd.cc2356r8
title: CCDC 1941429: Experimental Crystal Structure Determination

description: Related Article: Niloufar Akbarzadeh-T|2019|CSD Communication|||
DOI: 10.25318/1310042101-fra
title: Naissances vivantes, selon l'âge et la parité de la mère

description: Nombre et pourcentage de naissances vivantes, selon le groupe d'âge et la parité de la mère, de 1991 à l'année la plus récente.
DOI: 10.25318/1310045001-eng
title:  Patient satisfaction with most recent family doctor or other physician care received in the past 12 months

description: Patient satisfaction with most recent family doctor or other physician care received in the past 12 months, by age group and sex, household population aged 15 and over, Canadian Community Health Survey (CCHS 1.1, 2.1 and 3.1), Canada, provinces and territories.
DOI: 10.25318/1310045301-fra
title: Indicateurs de la santé, taux normalisés selon l'âge, estimations annuelles

description: Indicateurs de la santé, taux normalisés selon l'âge, estimations annuelles, selon le sexe, Canada, provinces et territoires.
DOI: 10.25318/3310011001-eng
title: Head offices and head office employment

description: The Census data which include: head offices and head office employment (NAICS 551114), annual, for two years of data.
DOI: 10.25318/3310011001-fra
title: Sièges sociaux et emploi dans les sièges sociaux

description: Les données du recensement pour sièges sociaux et emploi dans les sièges sociaux (SCIAN 551114), annuel, couvrant deux années de données.
DOI: 10.26126/intervals.tr7zkd
title: mRNA [Contrast]

description: This study reports a comparative assessment of the biological impact of a heated tobacco aerosol from the tobacco heating system (THS) 2.2 and smoke from a combustible 3R4F cigarette on human organotypic bronchial epithelium tissue exposed at the air-liquid interface. 
The transcriptome (mRNAs) was characterized using Affymetrix GeneChip® Human Genome U133 2.0 Arrays.
This dataset contains the statistics resulting from the comparison of treatment and control groups.
DOI: 10.5517/ccdc.csd.cc1zd24l
title: CCDC 1828849: Experimental Crystal Structure Determination

description: Related Article: Andrei V. Churakov, Dmitry A. Grishanov, Alexander G. Medvedev, Alexey A. Mikhaylov, Tatiana A. Tripol'skaya, Mikhail V. Vener, Mger A. Navasardyan, Ovadia Lev, Petr V. Prikhodchenko|2019|CrystEngComm|21|4961|doi:10.1039/C9CE00892F
DOI: 10.5517/ccdc.csd.cc1zd25m
title: CCDC 1828850: Experimental Crystal Structure Determination

description: Related Article: Andrei V. Churakov, Dmitry A. Grishanov, Alexander G. Medvedev, Alexey A. Mikhaylov, Tatiana A. Tripol'skaya, Mikhail V. Vener, Mger A. Navasardyan, Ovadia Lev, Petr V. Prikhodchenko|2019|CrystEngComm|21|4961|doi:10.1039/C9CE00892F
DOI: 10.5517/ccdc.csd.cc1zd27p
title: CCDC 1828852: Experimental Crystal Structure Determination

description: Related Article: Andrei V. Churakov, Dmitry A. Grishanov, Alexander G. Medvedev, Alexey A. Mikhaylov, Tatiana A. Tripol'skaya, Mikhail V. Vener, Mger A. Navasardyan, Ovadia Lev, Petr V. Prikhodchenko|2019|CrystEngComm|21|4961|doi:10.1039/C9CE00892F
DOI: 10.5517/ccdc.csd.cc224gmb
title: CCDC 1910921: Experimental Crystal Structure Determination

description: Related Article: Ryohei Katayama, Bo Gong, Noriko Togashi, Masaya Miyamoto, Masaki Kiga, Shiho Iwasaki, Yasuki Kamai, Yuichi Tominaga, Yasuyuki Takeda, Yoshiko Kagoshima, Yuki Shimizu, Yosuke Seto, Tomoko Oh-hara, Sumie Koike, Naoki Nakao, Hiroyuki Hanzawa, Kengo Watanabe, Satoshi Yoda, Noriko Yanagitani, Aaron N. Hata, Alice T. Shaw, Makoto Nishio, Naoya Fujita, Takeshi Isoyama|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc22g0f0
title: CCDC 1920091: Experimental Crystal Structure Determination

description: Related Article: Anastasia L. G. Kanegusuku, Thomas Castanheiro, Suraj K. Ayer, Jennifer L. Roizen|2019|Org.Lett.|21|6089|doi:10.1021/acs.orglett.9b02234
DOI: 10.5517/ccdc.csd.cc2357cx
title: CCDC 1941448: Experimental Crystal Structure Determination

description: Related Article: Alejandro Sanchez-Perucha, Michael Bolte|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc236gb4
title: CCDC 1942625: Experimental Crystal Structure Determination

description: Related Article: F. Gutzeit, C. Näther, R. Herges|2019|Acta Crystallogr.,Sect.E:Cryst.Commun.|75|1180|doi:10.1107/S2056989019009836
DOI: 10.25318/3310013801-eng
title: Employer enterprise deaths

description: Employer enterprise deaths, by North American Industry Classification System (NAICS) and enterprise size.
DOI: 10.25318/3610060001-eng
title: Cannabis supply, use and gross domestic product

description: Supply, use, and gross domestic product by medical and non-medical use, Canada, annual.
DOI: 10.25318/3610060001-fra
title: Offre et consommation de cannabis, produit intérieur brut

description: Offre et consommation de cannabis et produit intérieur brut par l'utilisation à des fins médicales et non médicales, Canada, annuel.
DOI: 10.25318/3610060201-fra
title: Titres d'emprunt émis par secteur, devise, échéance, type de taux d'intérêt, et marché d'émission (transactions nettes), trimestriel

description: Données trimestrielles de transactions nettes pour les titres d'emprunt émis selon le secteur, la devise, l'échéance, le type de taux d'intérêt et le marché d'émission.
DOI: 10.5517/ccdc.csd.cc2258j2
title: CCDC 1911693: Experimental Crystal Structure Determination

description: Related Article: Filip Zechel, Peter Schwendt, Róbert Gyepes, Ján Šimunek, Jozef Tatiersky, Lukáš Krivosudský|2019|New J.Chem.|43|17696|doi:10.1039/C9NJ02275A
DOI: 10.5517/ccdc.csd.cc2357dy
title: CCDC 1941449: Experimental Crystal Structure Determination

description: Related Article: Alejandro Sanchez-Perucha, Michael Bolte|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc235xdm
title: CCDC 1942100: Experimental Crystal Structure Determination

description: Related Article: Minghua Gong, Jingcheng Guo, Pengrui Jiang, Ye Zhang, Zhenqian Fu, Wei Huang|2020|Chem.Asian J.|15|352|doi:10.1002/asia.201901517
description: Related Article: gong minghua|2019|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc235xfn
title: CCDC 1942101: Experimental Crystal Structure Determination

description: Related Article: Biswa Nath Ghosh|2019|CSD Communication|||
DOI: 10.7939/dvn/pq2b0j/5mhw2n
title: Time_variable_constant_head_boundary.tab
DOI: 10.7939/dvn/pq2b0j/bielyz
title: Groundwater_Level_calibration_verif_data.tab
DOI: 10.7939/dvn/pq2b0j/cd8s0j
title: Access_tube_calibration_verif_data.tab
DOI: 10.7939/dvn/pq2b0j/d1etes
title: Atmospheric_Fluxes.tab
DOI: 10.25318/2510002101-eng
title: Electric power, electric utilities and industry, annual supply and disposition

description: Supply and disposition characteristics of electric power are presented, such as generation, imports, exports, sales and others. Data are presented at the national and provincial levels, not all combinations are available. These data include estimates (Electricity quantity and Electricity value).
DOI: 10.25318/2510002101-fra
title: L'énergie électrique, services d'électricité et d'industrie, disponibilité et écoulement, annuel

description: Les éléments de disponibilité et d'écoulement de l'énergie électriques sont présentés, incluant la production, les importations, les exportations, les ventes, et d'autres. Les données sont présentées aux niveaux national et provincial, par contre les combinaisons ne sont pas toutes disponibles. Ces données incluent des estimations (quantité d'électricité et valeur d'électricité).
DOI: 10.25318/2510002201-eng
title: Installed plants, annual generating capacity by type of electricity generation

description: Data presented at the national and provincial levels, however not all combinations are available. Electric power generating capacity by class of electricity producer (public and private electric utilities, as well as industries) and type of electricity generation (Hydraulic turbine, Wind power turbine, Tidal power turbine, etc).
DOI: 10.25318/2510002201-fra
title: Centrales installée, puissance génératrice annuelle selon le type de production d'électricité

description: Les données sont présentées aux niveaux national et provincial, par contre les combinaisons ne sont pas toutes disponibles. Puissance des centrales, par classe de producteur d'électricité (services publics d'électricité, services privés d'électricité et les industries) et par type de production d'électricité (Turbine à hydraulique, turbine éolienne, turbine marémotrice, etc.).
DOI: 10.6084/m9.figshare.17306291
title: Extreme Storm Events Shift DOC Export from Transport-limited to Source-limited in a Typical Flash Flood Catchment

description: DOC dynamics of a flash
flood catchment were investigated in this study with high-frequency observations
during flood seasons. <br>
DOI: 10.6084/m9.figshare.20452025
title: Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis

description: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis that seriously threatens women’s health. There is still a lack of effective therapeutic targets for TNBC treatment. We conducted a meta-analysis to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1)/programmed death protein ligand 1 (PD-L1) inhibitors in combination with chemotherapy for TNBC patients. We searched PubMed, EMBASE, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) related to PD-1/PD-L1 inhibitors combined with chemotherapy. Literature conforming to the research content was identified according to the inclusion and exclusion criteria. The endpoints of efficacy were pathological complete response (pCR), event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). Safety outcomes included adverse events (AEs) of any grade, AEs of grade ≥3, serious AEs, and the incidence of various AEs. We obtained odds ratios (OR), hazard ratio (HR), and 95% confidence interval (CI) for the included studies. Data analysis was performed using Review Manager software (version 5.3). A total of 4468 patients from eight RCTs were analyzed. PD-1/PD-L1 inhibitors in combination with chemotherapy significantly improved pCR (OR, 1.59; 95% CI, 1.28 − 1.98, <i>p</i> &lt; 0.0001), EFS (HR, 0.66; 95% CI, 0.48 − 0.91, <i>p</i> = 0.01), and OS (HR, 0.72; 95% CI, 0.52 − 0.99, <i>p</i> = 0.05) in patients with TNBC compared to chemotherapy alone or placebo in combination with chemotherapy. Furthermore, we found that the pCR rate was almost identical in the PD-L1 positive group (OR, 1.65; 95% CI, 1.26 − 2.16, <i>p</i> = 0.0002) and the PD-L1 negative group (OR, 1.56; 95% CI, 1.04 − 2.33, <i>p</i> = 0.03). Among patients with advanced-stage TNBC, PFS (HR, 0.82; 95% CI, 0.74 − 0.90, <i>p</i> &lt; 0.0001) was longer in the combination therapy group than in the chemotherapy group. There were no statistically significant differences between the experimental and control groups in OS (HR, 1.03; 95% CI, 0.74 − 1.42, <i>p</i> = 0.87). In terms of safety, we found that the combination therapy group had a significantly higher incidence of hyperthyroidism in patients with early and advanced TNBC (OR, 5.76; 95% CI, 2.38 − 13.95, <i>p</i> = 0.0001) (OR, 7.86; 95% CI, 2.65 − 23.29, <i>p</i> = 0.0002). The combination of PD-1/PD-L1 inhibitors and chemotherapy could improve the survival and prognosis of patients with early and advanced TNBC. Combination treatment may be harmful to the thyroid; therefore, active surveillance and regular follow-up are necessary during treatment.
DOI: 10.6084/m9.figshare.20452025.v1
title: Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis

description: Triple-negative breast cancer (TNBC) is a subtype of breast cancer with a poor prognosis that seriously threatens women’s health. There is still a lack of effective therapeutic targets for TNBC treatment. We conducted a meta-analysis to evaluate the efficacy and safety of programmed cell death protein 1 (PD-1)/programmed death protein ligand 1 (PD-L1) inhibitors in combination with chemotherapy for TNBC patients. We searched PubMed, EMBASE, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) related to PD-1/PD-L1 inhibitors combined with chemotherapy. Literature conforming to the research content was identified according to the inclusion and exclusion criteria. The endpoints of efficacy were pathological complete response (pCR), event-free survival (EFS), progression-free survival (PFS), and overall survival (OS). Safety outcomes included adverse events (AEs) of any grade, AEs of grade ≥3, serious AEs, and the incidence of various AEs. We obtained odds ratios (OR), hazard ratio (HR), and 95% confidence interval (CI) for the included studies. Data analysis was performed using Review Manager software (version 5.3). A total of 4468 patients from eight RCTs were analyzed. PD-1/PD-L1 inhibitors in combination with chemotherapy significantly improved pCR (OR, 1.59; 95% CI, 1.28 − 1.98, <i>p</i> &lt; 0.0001), EFS (HR, 0.66; 95% CI, 0.48 − 0.91, <i>p</i> = 0.01), and OS (HR, 0.72; 95% CI, 0.52 − 0.99, <i>p</i> = 0.05) in patients with TNBC compared to chemotherapy alone or placebo in combination with chemotherapy. Furthermore, we found that the pCR rate was almost identical in the PD-L1 positive group (OR, 1.65; 95% CI, 1.26 − 2.16, <i>p</i> = 0.0002) and the PD-L1 negative group (OR, 1.56; 95% CI, 1.04 − 2.33, <i>p</i> = 0.03). Among patients with advanced-stage TNBC, PFS (HR, 0.82; 95% CI, 0.74 − 0.90, <i>p</i> &lt; 0.0001) was longer in the combination therapy group than in the chemotherapy group. There were no statistically significant differences between the experimental and control groups in OS (HR, 1.03; 95% CI, 0.74 − 1.42, <i>p</i> = 0.87). In terms of safety, we found that the combination therapy group had a significantly higher incidence of hyperthyroidism in patients with early and advanced TNBC (OR, 5.76; 95% CI, 2.38 − 13.95, <i>p</i> = 0.0001) (OR, 7.86; 95% CI, 2.65 − 23.29, <i>p</i> = 0.0002). The combination of PD-1/PD-L1 inhibitors and chemotherapy could improve the survival and prognosis of patients with early and advanced TNBC. Combination treatment may be harmful to the thyroid; therefore, active surveillance and regular follow-up are necessary during treatment.
DOI: 10.6084/m9.figshare.19927737
title: Increased blood pressure variability predicts poor outcomes from endovascular treatment for aneurysmal subarachnoid hemorrhage

description: ABSTRACT Background: Predictors of outcomes following endovascular treatment (ET) for aneurysmal subarachnoid hemorrhage (aSAH) are not well-defined. Identifying them would be beneficial in determining which patients might benefit from ET. Objective: To identify the predictive factors for poor outcomes following ET for aSAH. Methods: 120 patients with ruptured cerebral aneurysms underwent endovascular embolization between January 2017 and December 2018. Blood pressure variability was examined using the standard deviation of the 24-hour systolic blood pressure (24hSSD) and 24-hour diastolic blood pressure (24hDSD). Predictors were identified through univariate and multivariate regression analysis. All patients were followed up for three months. Results: At follow-up, 86 patients (71.7%) had good outcomes and 34 (28.3%) had poor outcomes. Patients with poor outcomes had significantly higher 24hSSD than those with good outcomes (19.3 ± 5.5 vs 14.1 ± 4.8 mmHg; P &lt; 0.001). The 24hDSD did not differ significantly between patients with good outcomes and those with poor outcomes (9.5 ± 2.3 vs 9.9 ± 3.5 mmHg; P = 0.464). The following were significant risk factors for poor outcomes after endovascular embolization: age ≥ 65 years (odds ratio [OR] = 23.0; 95% confidence interval [CI]: 3.0-175.9; P = 0.002); Hunt-Hess grade 3-4 (OR = 6.8; 95% CI: 1.1-33.7; P = 0.039); Fisher grade 3-4 (OR = 47.1; 95% CI: 3.8-586.5; P = 0.003); postoperative complications (OR = 6.1; 95% CI: 1.1-34.8; P = 0.042); and 24hSSD ≥ 15 mmHg (OR = 14.9; 95% CI: 4.0-55.2; P &lt; 0.001). Conclusion: Elevated 24hSSD is a possibly treatable predictive factor for poor outcomes after ET for aSAH.
DOI: 10.6084/m9.figshare.19927737.v1
title: Increased blood pressure variability predicts poor outcomes from endovascular treatment for aneurysmal subarachnoid hemorrhage

description: ABSTRACT Background: Predictors of outcomes following endovascular treatment (ET) for aneurysmal subarachnoid hemorrhage (aSAH) are not well-defined. Identifying them would be beneficial in determining which patients might benefit from ET. Objective: To identify the predictive factors for poor outcomes following ET for aSAH. Methods: 120 patients with ruptured cerebral aneurysms underwent endovascular embolization between January 2017 and December 2018. Blood pressure variability was examined using the standard deviation of the 24-hour systolic blood pressure (24hSSD) and 24-hour diastolic blood pressure (24hDSD). Predictors were identified through univariate and multivariate regression analysis. All patients were followed up for three months. Results: At follow-up, 86 patients (71.7%) had good outcomes and 34 (28.3%) had poor outcomes. Patients with poor outcomes had significantly higher 24hSSD than those with good outcomes (19.3 ± 5.5 vs 14.1 ± 4.8 mmHg; P &lt; 0.001). The 24hDSD did not differ significantly between patients with good outcomes and those with poor outcomes (9.5 ± 2.3 vs 9.9 ± 3.5 mmHg; P = 0.464). The following were significant risk factors for poor outcomes after endovascular embolization: age ≥ 65 years (odds ratio [OR] = 23.0; 95% confidence interval [CI]: 3.0-175.9; P = 0.002); Hunt-Hess grade 3-4 (OR = 6.8; 95% CI: 1.1-33.7; P = 0.039); Fisher grade 3-4 (OR = 47.1; 95% CI: 3.8-586.5; P = 0.003); postoperative complications (OR = 6.1; 95% CI: 1.1-34.8; P = 0.042); and 24hSSD ≥ 15 mmHg (OR = 14.9; 95% CI: 4.0-55.2; P &lt; 0.001). Conclusion: Elevated 24hSSD is a possibly treatable predictive factor for poor outcomes after ET for aSAH.
DOI: 10.6084/m9.figshare.21500622
title: Additional file 1 of Characterization of diazotrophic root endophytes in Chinese silvergrass (Miscanthus sinensis)

description: Additional file 1: Table S1. The chemical properties of sample sites. Table S2. Node table for biotic interaction network in the less contaminatedsites. Table S3. Edge table for biotic interaction network in the lesscontaminated sites. Table S4. Node table for biotic interaction network in thehigh contaminated sites. Table S5. Edge table for biotic interaction network inthe high contaminated sites.
DOI: 10.6084/m9.figshare.21500622.v1
title: Additional file 1 of Characterization of diazotrophic root endophytes in Chinese silvergrass (Miscanthus sinensis)

description: Additional file 1: Table S1. The chemical properties of sample sites. Table S2. Node table for biotic interaction network in the less contaminatedsites. Table S3. Edge table for biotic interaction network in the lesscontaminated sites. Table S4. Node table for biotic interaction network in thehigh contaminated sites. Table S5. Edge table for biotic interaction network inthe high contaminated sites.
DOI: 10.6084/m9.figshare.5771991
title: Integrative transcriptome analysis identifies genes and pathways associated with enzalutamide resistance of prostate cancer

description: <b>Background:</b> Enzalutamide, a novel androgen receptor (AR) signaling inhibitor, has been widely used to increase survival in patients with castration-resistant prostate cancer. However, resistance to enzalutamide invariably develops. <b>Methods:</b> To understand the underlying mechanisms of resistance to enzalutamide, we performed integrative analysis on multiple transcriptome datasets to identify those genes constantly up- or down-regulated in response to enzalutamide treatment. <b>Results:</b> There were 703 and 581 differentially expressed genes derived from enzalutamide-sensitive and -resistant cell lines, respectively. Functional enrichment analysis on these genes demonstrated that biological processes of cell proliferation and ubiquitin mediated proteolysis pathway are specifically disturbed in sensitive cell lines but not resistant ones. Such divergence explained why enzalutamide ineffective for resistant prostate cancer. <b>Conclusions:</b> Taken together, the present study revealed a set of critical genes, which can provide etiologic clues as to enzalutamide-resistant prostate cancer and guide novel therapeutic approaches.
DOI: 10.25318/1310087401-fra
title: Caractéristiques socioéconomiques de la population 2ELGBTQ&#43;, 2019 à 2021

description: Caractéristiques socio-économiques des personnes âgées de 15 ans et plus qui sont bispirituelles, lesbiennes, gaies, bisexuelles, transgenres et queers ainsi que celles qui emploient d'autres termes relatifs à la diversité sexuelle ou de genre (2ELGBTQ+), selon le genre de la personne, le groupe d'âge et la région géographique. L'état civil, la présence d'enfants de moins de 12 ans dans le ménage, la scolarité, l'emploi, le revenu personnel, l'identité autochtone, la population des minorités visibles, le statut d'immigrant, la ou les langues parlées le plus souvent à la maison, le lieu de résidence (centre de population/rural), l'état de santé général et l'état de santé mentale autoévalués. Les estimations sont obtenues à partir des cycles combinés de l'Enquête sur la santé dans les collectivités canadiennes, 2019 à 2021.
DOI: 10.6084/m9.figshare.14684895
title: Additional file 13 of Population transcriptomic sequencing reveals allopatric divergence and local adaptation in Pseudotaxus chienii (Taxaceae)

description: Additional file 13. The annotation of the unigenes containing outlier SNPs.
DOI: 10.6084/m9.figshare.14684895.v1
title: Additional file 13 of Population transcriptomic sequencing reveals allopatric divergence and local adaptation in Pseudotaxus chienii (Taxaceae)

description: Additional file 13. The annotation of the unigenes containing outlier SNPs.